Levi & Korsinsky, LLP announces that a FREQ class action lawsuit has been filed on behalf of investors who purchased Frequency Therapeutics, Inc. (FREQ) securities between November 16, 2020 and March 22, 2021. For more on the FREQ Lawsuit please contact us today.
According to the Frequency Therapeutics, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
the Company’s Phase 2a trial results failed to live up to the Company’s expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322’s potential. These statements materially misled the market and artificially inflated the value of Frequency’s common stock.
If you suffered a loss in Frequency Therapeutics, Inc. you have until August 2, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.